ArticleScientific reports2026
Enhanced meropenem activity by a microbiome derived peptide targeting oxacillinase 48 carbapenemase in carbapenem resistant Klebsiella pneumoniae isolates.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Carbapenem-resistant Enterobacterales, particularly those producing oxacillinase 48 (OXA-48) carbapenemase (blaOXA−48), pose a critical global health threat, especially in the Middle East where its prevalence is remarkably high. The lack of specific OXA-48 inhibitors and the emergence of resistance even to avibactam highlight the urgent need for novel therapeutic strategies. This study investigated the peptide M104 as an adjunctive agent to meropenem against multidrug-resistant (including meropenem-resistant) blaOXA−48 positive Klebsiella pneumoniae clinical isolates. Peptide M104 at the concentration of 125 µg/mL enhanced meropenem’s antibacterial activity against all ten tested blaOXA−48 positive isolates and significantly reduced the meropenem minimum inhibitory concentration (MIC) values at least two-fold for all ten clinical isolates (p-value < 0.002). This enhancement was not observed in blaOXA−48 negative isolates, and the peptide showed no intrinsic antibacterial activity. In strong biofilm-forming isolates, M104 reduced meropenem’s minimum biofilm inhibitory concentrations (MBIC) by two-fold, although this reduction was not statistically significant (p-value = 0.06), and showed limited meropenem enhancement in reducing minimum biofilm eradication concentration (MBEC). Cytotoxicity assays revealed that M104 at 200 µg/mL did not reduce HDFa cell viability after 24 h, and the peptide also showed no hemolytic activity at this concentration. These findings suggest peptide M104 is a candidate OXA-48 inhibitor, capable of enhancing meropenem’s efficacy against carbapenem-resistant K. pneumoniae infections, while showing limited cytotoxicity and no hemolytic effects. Further validation using a larger number of clinical isolates and in vivo studies is needed to confirm these results and support peptide M104 as the first peptide inhibitor of OXA-48 carbapenemase.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.